# Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer

> **NCT04675697** · PHASE2 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 36 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Platinum-etoposide+Anlotinib

## Key facts

- **NCT ID:** NCT04675697
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-24
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2020-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04675697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04675697, "Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04675697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*